Celastrol attenuates the inflammatory response by inhibiting IL‑1β expression in triple‑negative breast cancer cells

You,Daeun; Jeong,Yisun; Yoon,Sun Young; A Kim,Sung; Kim,Seok Won; Nam,Seok Jin; Lee,Jeong Eon; Kim,Sangmin

doi:10.3892/or.2021.8040

Celastrol attenuates the inflammatory response by inhibiting IL‑1β expression in triple‑negative breast cancer cells

Authors:
- Daeun You
- Yisun Jeong
- Sun Young Yoon
- Sung A Kim
- Seok Won Kim
- Seok Jin Nam
- Jeong Eon Lee
- Sangmin Kim
View Affiliations

Affiliations: Department of Health Sciences and Technology, The Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06351, Republic of Korea, Department of Breast Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
Published online on: April 2, 2021 https://doi.org/10.3892/or.2021.8040
Article Number: 89
Copyright: © You et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

IL‑1 promotes cancer cell proliferation and invasiveness in various malignancies, such as breast and colorectal cancer. In the present study, the functional roles of IL‑1β (IL1B) and the inhibitory effect of celastrol on IL1B expression were investigated in triple‑negative breast cancer (TNBC) cells. The data revealed that celastrol markedly decreased IL1B expression and suppressed TNBC cell proliferation in a dose‑dependent manner. The levels of IL1B and IL8 mRNA were significantly increased in TNBC cells compared with non‑TNBC cells. In addition, IL1B augmented the expression levels of IL8 as well as matrix metalloproteinases (MMPs), including MMP‑1 and MMP‑9, in TNBC cells. Furthermore, IL1B expression was decreased by a specific MEK1/2 inhibitor, MEK162. Celastrol also promoted IL1B downregulation through the suppression of the MEK/ERK‑dependent pathway. Furthermore, the results also revealed a decrease in IL1B‑induced IL8, MMP‑1, and MMP‑9 expression in response to celastrol treatment. The induction of cellular invasion by IL1B was also markedly decreased by celastrol. Collectively, the present study results suggested celastrol as an effective drug for the treatment of TNBC, involving a reduction in IL1B expression, activity or signaling pathways.

View Figures

View References

1	Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al: Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone AM, et al: Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 107:djv0482015. View Article : Google Scholar : PubMed/NCBI
3	Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
4	Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
5	Boyle P: Triple-negative breast cancer: Epidemiological considerations and recommendations. Ann Oncol. 23 (Suppl 6):vi7–vi12. 2012. View Article : Google Scholar : PubMed/NCBI
6	Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011. View Article : Google Scholar : PubMed/NCBI
7	Lee HW, Jang KS, Choi HJ, Jo A, Cheong JH and Chun KH: Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy. BMB Rep. 47:697–702. 2014. View Article : Google Scholar : PubMed/NCBI
8	Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, et al: Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila). 5:631–643. 2012. View Article : Google Scholar : PubMed/NCBI
9	Lin L, Sun Y, Wang D, Zheng S, Zhang J and Zheng C: Celastrol ameliorates ulcerative colitis-related colorectal cancer in mice via suppressing inflammatory responses and epithelial-mesenchymal transition. Front Pharmacol. 6:3202015.PubMed/NCBI
10	Zhao J, Sun Y, Shi P, Dong JN, Zuo LG, Wang HG, Gong JF, Li Y, Gu LL, Li N, et al: Celastrol ameliorates experimental colitis in IL-10 deficient mice via the up-regulation of autophagy. Int Immunopharmacol. 26:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
11	Broide DH: Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol. 108((2 Suppl)): S65–S71. 2001. View Article : Google Scholar : PubMed/NCBI
12	Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 4:11–22. 2004. View Article : Google Scholar : PubMed/NCBI
13	Jeon M, Han J, Nam SJ, Lee JE and Kim S: Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone. Chem Biol Interact. 258:126–133. 2016. View Article : Google Scholar : PubMed/NCBI
14	Shao N, Lu Z, Zhang Y, Wang M, Li W, Hu Z, Wang S and Lin Y: Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway. Cancer Lett. 364:165–172. 2015. View Article : Google Scholar : PubMed/NCBI
15	Han J, Bae SY, Oh SJ, Lee J, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Nam SJ, et al: Zerumbone suppresses IL-1β-induced cell migration and invasion by inhibiting IL-8 and MMP-3 expression in human triple-negative breast cancer cells. Phytother Res. 28:1654–1660. 2014. View Article : Google Scholar : PubMed/NCBI
16	Lewis AM, Varghese S, Xu H and Alexander HR: Interleukin-1 and cancer progression: The emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 4:482006. View Article : Google Scholar : PubMed/NCBI
17	Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X, et al: Endogenous production of IL-1Β by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin Cancer Res. 25:2769–2782. 2019. View Article : Google Scholar : PubMed/NCBI
18	Todorović-Rakovic N and Milovanović J: Interleukin-8 in breast cancer progression. J Interferon Cytokine Res. 33:563–570. 2013. View Article : Google Scholar : PubMed/NCBI
19	Kim S, Lee J, Jeon M, Lee JE and Nam SJ: MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells. Tumour Biol. 37:4991–4999. 2016. View Article : Google Scholar : PubMed/NCBI
20	Kim S, You D, Jeong Y, Yoon SY, Kim SA, Kim SW, Nam SJ and Lee JE: WNT5A augments cell invasiveness by inducing CXCL8 in HER2-positive breast cancer cells. Cytokine. 135:1552132020. View Article : Google Scholar : PubMed/NCBI
21	Kim S, You D, Jeong Y, Yu J, Kim SW, Nam SJ and Lee JE: Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells. Phytomedicine. 50:43–49. 2018. View Article : Google Scholar : PubMed/NCBI
22	Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
23	Dmitrieva OS, Shilovskiy IP, Khaitov MR and Grivennikov SI: Interleukins 1 and 6 as main mediators of inflammation and cancer. Biochemistry (Mosc). 81:80–90. 2016. View Article : Google Scholar : PubMed/NCBI
24	Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, Barrows G and Kreutzer DL: The interleukin-1 family of cytokines and receptors in human breast cancer: Implications for tumor progression. Int J Oncol. 23:269–284. 2003.PubMed/NCBI
25	Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, Lindquist R, Barrows G and Kreutzer DL: Interleukin-1 family expression in human breast cancer: Interleukin-1 receptor antagonist. Cancer Invest. 18:293–302. 2000. View Article : Google Scholar : PubMed/NCBI
26	Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM and Alexander HR: The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res. 12:1088–1096. 2006. View Article : Google Scholar : PubMed/NCBI
27	Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al: Expression of interleukin-1beta in human breast carcinoma. Cancer. 80:421–434. 1997. View Article : Google Scholar : PubMed/NCBI
28	Ma L, Lan F, Zheng Z, Xie F, Wang L, Liu W, Han J, Zheng F, Xie Y and Huang Q: Epidermal growth factor (EGF) and interleukin (IL)-1β synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion. Mol Cancer. 11:792012. View Article : Google Scholar : PubMed/NCBI
29	Yoshimura H, Nakahama K, Safronova O, Tanaka N, Muneta T and Morita I: Transforming growth factor-beta stimulates IL-1beta-induced monocyte chemoattractant protein-1 expression in human synovial cells via the ERK/AP-1 pathway. Inflamm Res. 55:543–549. 2006. View Article : Google Scholar : PubMed/NCBI
30	Dinarello CA: Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 27:519–550. 2009. View Article : Google Scholar : PubMed/NCBI
31	Hou Z, Falcone DJ, Subbaramaiah K and Dannenberg AJ: Macrophages induce COX-2 expression in breast cancer cells: Role of IL-1β autoamplification. Carcinogenesis. 32:695–702. 2011. View Article : Google Scholar : PubMed/NCBI
32	Collins TS, Lee LF and Ting JP: Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol Immunother. 49:78–84. 2000. View Article : Google Scholar : PubMed/NCBI
33	Westermarck J and Kahari VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13:781–792. 1999. View Article : Google Scholar : PubMed/NCBI
34	Jackson BC, Nebert DW and Vasiliou V: Update of human and mouse matrix metalloproteinase families. Hum Genomics. 4:194–201. 2010. View Article : Google Scholar : PubMed/NCBI
35	Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
36	Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, et al: Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol. 164:1506–1521. 2011. View Article : Google Scholar : PubMed/NCBI
37	Lee JH, Won YS, Park KH, Lee MK, Tachibana H, Yamada K and Seo KI: Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT signaling. Apoptosis. 17:1275–1286. 2012. View Article : Google Scholar : PubMed/NCBI
38	Mou H, Zheng Y, Zhao P, Bao H, Fang W and Xu N: Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways. Toxicol In Vitro. 25:1027–1032. 2011. View Article : Google Scholar : PubMed/NCBI
39	Li H, Yuan Y, Zhang Y, He Q, Xu R, Ge F and Wu C: Celastrol inhibits IL-1β-induced inflammation in orbital fibroblasts through the suppression of NF-κB activity. Mol Med Rep. 14:2799–2806. 2016. View Article : Google Scholar : PubMed/NCBI
40	Zhang J, Zhou K, Zhang X, Zhou Y, Li Z and Shang F: Celastrol ameliorates inflammation in human retinal pigment epithelial cells by suppressing NF-κB signaling. J Ocul Pharmacol Ther. 35:116–123. 2019. View Article : Google Scholar : PubMed/NCBI
41	Kim Y, Kang H, Jang SW and Ko J: Celastrol inhibits breast cancer cell invasion via suppression of NF-kB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem. 28:175–184. 2011. View Article : Google Scholar : PubMed/NCBI
42	Park S, Jung HH, Park YH, Ahn JS and Im YH: ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression. Biochem Biophys Res Commun. 407:680–686. 2011. View Article : Google Scholar : PubMed/NCBI
43	Hashimoto K, Otero M, Imagawa K, de Andrés MC, Coico JM, Roach HI, Oreffo RO, Marcu KB and Goldring MB: Regulated transcription of human matrix metalloproteinase 13 (MMP13) and interleukin-1β (IL-1Β) genes in chondrocytes depends on methylation of specific proximal promoter CpG sites. J Biol Chem. 288:10061–10072. 2013. View Article : Google Scholar : PubMed/NCBI